Menu Close

Affyimmune Therapeutics, Inc.

Affyimmune Therapeutics logo
  • AffyImmune’s core focus is on developing CAR T cells effective in treating solid tumors, which account for over 90% of all cancer fatalities. Our Phase I clinical trial of our lead compound in patients with anaplastic or refractory thyroid cancer is now enrolling patients (NCT04420754)
  • AffyImmune is a clinical stage biotechnology company focused on developing technologies that expand the utility and improve the safety of cell-based immunotherapy for cancer.